Idiopathic Pulmonary Fibrosis: Fibroblasts More Agresssive With USP13 Loss

How Esbriet (pirfenidone) Works?

Esbriet is an anti-inflammatory and anti-fibrotic drug that reduces inflammation and fibrosis simultaneously. Learn more: http://bit.ly/Esbriet Note: Pulmonary Fibrosis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This…

History of Esbriet (pirfenidone)

While the therapy was approved for use in 2014 in the US, Japan was the first country to approve its commercial use in 2008, followed by India in 2010, Europe in 2011, and China in 2013. Because IPF is considered a rare condition, this drug was…

What It’s Like To Live With IPF?

“Watch the video shared by the Canadian Pulmonary Fibrosis Foundation to understand what is like to live with IPF through the eyes of patients and their families.” Learn more about Esbriet that addresses Idiopathic Pulmonary Fibrosis: http://bit.ly/Esbriet…

IPF Experts Discuss Disease Diagnosis and Treatment at CHEST 2015

The American College of Chest Physicians Annual Meeting (CHEST 2015), held Oct. 24–28 in Montreal, Canada, included a breakfast symposium where a panel of experts shared practical tips to help clinicians assess, diagnose, and manage idiopathic pulmonary fibrosis (IPF) and co-morbidities linked to the disease. Dr. Timothy Whelan, associate professor…

OFEV® (Nintedanib) Efficacy Supported in New Study

Boehringer Ingelheim Pharmaceuticals recently presented results of the Phase III INPULSIS trials investigating the efficacy of OFEV® (nintedanib) in patients with idiopathic pulmonary fibrosis (IPF) at the American College of Chest Physicians Annual Meeting (CHEST 2015). The Phase III INPULSIS trials were randomized, double-blind studies designed to assess both the efficacy and safety…

LARIAT Trial Shows Benefits of Reata’s Bardoxolone Methyl in Treating Fibrosis and Inflammation in PAH

Reata Pharmaceuticals, a clinical-stage biopharmaceutical company, recently presented results from the LARIAT trial investigating the drug bardoxolone methyl in patients with pulmonary arterial hypertension (PAH). The study entitled “Bardoxolone Methyl Evaluation in Patients with Pulmonary Arterial Hypertension (PAH)” was presented in the 2015 American College…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums